Bioprocess Technology Market Size to Hit USD 53.30 Bn by 2030

According to Nova one advisor, the global Bioprocess Technology market size is expected to hit around USD 53.30 billion by 2030 from valued at USD 23.45 billion in 2021 and growing at a CAGR of 9.7% from 2022 to 2030.

Request Free Sample of This Report@ https://www.novaoneadvisor.com/report/sample/7119

Bioprocess Technology Market: Overview

• Bioprocess technology is the industrial application of biological processes, which include living cells with their components to upshot the transformation of substrate
• Bioprocess includes various activities such as biocatalyst, bioreactors, purification, upstream processes, and downstream processes
• It has substantial demand in the pharma industry due to rise in prevalence of cancer & other chronic diseases
• Increase in the global geriatric population leads to a rise in patient population suffering from infections and diseases. According to the 2016 research findings by the World Health Organization (WHO), population aged 60 and above is projected to reach 2.5 billion by the end of 2050.
• More than 25% of the world’s population will be aged 65 by the end of 2050. Aging population is more prone to diseases such as chronic kidney diseases, diabetes, cardiovascular diseases, hypertension, and cancer due to low immunity. Hence, surge in the geriatric population increases the prevalence/incidence rate of these disorders and diseases.
• Rise in outsourcing of manufacturing activities to CMOs, CROs, and CDMOs is set to propel the single-use bioprocessing industry, as increasing number of CMOs have small flexible facilities and are beginning to rely on single-use equipment in their process value chain. This is likely to boost the global bioprocess technology market.

Report Scope of the Bioprocess Technology Market

    Ask here for more customization study@ https://www.novaoneadvisor.com/report/customization/7119

          Biopharmaceutical Companies Boosting R&D with Surging Number of Chronic Diseases

The high prevalence of cancer and other chronic diseases is fueling the demand for innovations in the bioprocess technology. The ever-expanding pharmaceutical industry is translating into revenue opportunities for stakeholders in the global bioprocess technology market. The surge in the demand for vaccines and proteins has induced pharmaceutical and biotechnology companies to increase production of therapeutics, bolster research studies, and other investigations.

Biopharmaceutical outsourcing is emerging as a promising strategy to address the unmet medical needs among patients. This has led to rise in usage of bioprocessing systems with better process efficiency and throughput. These systems offer an advantage for adherence with regulatory compliance processes. An increasing number of biopharmaceutical companies are opting for single-use systems, as they deliver cost-efficiency and technological advancements due to growing capacities and capabilities.

Manufacturers Allocating Budgets to Ensure Resilient Supply Chains amid COVID-19 Pandemic

Manufacturers in the bioprocess technology market have been working at break-neck speeds amid the ongoing COVID-19 pandemic to ensure robust supply of consumables, instruments, cell counters, and the likes. As the U.S. and other regions of the world with high population such as India and Brazil are bracing themselves, Shanghai in China is yet again under great emphasis for the Wuhan virus.

Even as the production and movement of goods are slow, manufacturers are rethinking their budget for allocating sufficient capital & expenses to ensure business continuity. They are increasing the availability of life-saving medical devices to improve patient outcomes.

Investments in Bioprocess Hardware Helps Accelerate Turnaround Times

The bioprocess technology market is estimated to grow at a robust CAGR throughout the assessment period. However, this market is governed by stringent regulatory framework, since public health concerns are a top priority for CMOs (contract manufacturing organizations), CROs (contract research organizations), and CDMOs (contract development and manufacturing organizations).

Hence, stakeholders should increase R&D to expand their creation limits and reduce the turnaround time to introduce new medications in the market. Companies should invest in bioprocess hardware to offer imaginative, safe, and highly precise solutions to fulfill the expansion in need from biopharmaceutical organizations.

Cell-level Treatment Innovations Hold Potentials in Early Detection of Chronic Diseases

The lack of research for life-threatening health conditions such as the Crohn’s disease is creating opportunity windows for companies in the bioprocess technology market. Healthcare solutions at cell-level hold promising potentials to treat diseases at the foundation level. Cell-level treatment innovations have the capability to detect early symptoms of chronic diseases and can help to reduce its severity in future, thus benefitting patient quality of life. These strategies have the potential to increase life-expectancy, especially in the geriatric population. Thus, treatments that can alter the DNA at genetic level have the capability to improve patient outcomes.

Bioprocess Technology Being Enhanced with Constant R&D Activities

Constant innovations in the bioprocess technology market is leading to market expansion. Bioprocess technology finds application in end-use ventures for the assembling of biomaterials such as catalysts, anti-microbial medications, food & farming items, antibodies, and drug supplements. Moreover, this technology tracks down the application for the creation of biodegradable & climate agreeable chemicals, development of elective items to treat diseases, and facilitate the creation & assessment of more secure food materials.

As procedures and instrumentation become additionally modern, bioprocesses may find applications in different areas where substance processes are presently utilized. Biological, engineering, and mathematical processes are being pooled to achieve bioprocessing activities such as media production, biocatalysts, and the designing of bioreactor substrates. Companies in the bioprocess technology market are gaining cognizance about the benefits of the single-use bioprocessing technologies and are diversifying into the adoption for hybrid systems in their facilities.

Bioprocess Technology Market: Segmentation

• The global bioprocess technology market has been segmented based on product, application, and end-user
• In terms of product, the global bioprocess technology market has been bifurcated into consumables & accessories and instruments
• Based on application, the global market has been classified into primary surgical, antibiotics, recombinant proteins, monoclonal antibodies, and biosimilar
• In terms of end-user, the global bioprocess technology market has been divided into biopharmaceutical companies, contract manufacturing organization, contract research organization, food & feed industry, and academic research organization
• Each of the segments has been analyzed in detail for recent trends & developments, drivers, restraints, opportunities, and useful insights. The bioprocess technology market report provides current and future revenue (US$ Mn) for each of these segments for the period from 2017 to 2030, considering 2020 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2021 to 2030, along with market size estimations.

Regional Overview: Bioprocess Technology Market

• In terms of region, the global bioprocess technology market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions. North America is projected to be a highly lucrative market during the forecast period. The region accounted major share of the global market in 2020. The market in North America is anticipated to expand at a high CAGR from 2021 to 2030.
• The U.S. dominated the market in North America in 2020, owing to factors such as increase in geriatric population and presence of a large number of bioprocess technology manufacturers. Additionally, availability of advanced technology and undertaking of a large number of research studies in the U.S. drive the market in the region.
• Europe was the second largest market for bioprocess technology in 2020. The market in the region is driven by expansion of the biopharmaceutical industry, rise in demand for different products such as antibiotics, bio-similar, monoclonal antibodies, recombinant proteins, and cost reductions of these products.

Some of the prominent players in the Bioprocess Technology Market include:

• Thermo Fisher Scientific, Inc.
• Siemens Healthineers
• GE Healthcare (General Electric Company)
• Sartorius AG
• Becton
• Dickinson and Company
• Danaher Corporation
• Eppendorf AG
• Lonza
• Advanced Instruments
• Nova Biomedical
• F. Hoffmann-La Roche Ltd.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Bioprocess Technology market

• Product
  • Consumables & Accessories
    • Culture Media
    • Reagents
    • Others
  • Instruments
    • Bioprocess Analyzers
    • Blood Gas Analyzers
    • Osmometers
    • Cell Counter
    • Incubators
    • Bioreactors
    • Others (centrifugation, spectrometer, filtration)
• Application
  • Primary Surgical
  • Antibiotics
  • Recombinant Proteins
  • Monoclonal Antibodies
  • Biosimilar
• End-user
  • Biopharmaceutical Companies
  • Contract Manufacturing Organization
  • Contract Research Organization
  • Food & Feed Industry
  • Academic Research Organization

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Full Report is Ready | For Purchase Inquiry@ https://www.novaoneadvisor.com/report/checkout/7119

You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com| +1 9197 992 333

Blog: https://www.novaoneadvisor.com/

Blog: https://www.visionresearchreports.com/

Blog: https://qyresearchmedical.com/